Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

ROS1 rearrangements are present in 1-2% of NSCLC cases and define a distinct molecular subgroup. Like ALK (anaplastic lymphoma kinase) rearrangements in NSCLC, ROS1 fusions confer sensitivity to

  • 0 views
  • 07 Jun, 2021
  • 39 locations
Vactosertib in Combination With Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

-L1 positive, non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease and in whom EGFR, ALK, BRAF, ROS1-directed therapy is not indicated.

  • 0 views
  • 29 Jan, 2021
  • 1 location
Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA

In patients with locally advanced or metastatic tumors, first-line therapeutic management is based on the use of targeted therapies (EGFR, BRAF ALK and ROS1 inhibitors), immunotherapies (anti

atezolizumab
BRAF
ROS1
pd-l1
metastasis
  • 5 views
  • 27 Jan, 2021
  • 2 locations
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements

repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on

cancer
ROS1
solid tumor
  • 338 views
  • 05 Feb, 2021
  • 132 locations
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK ROS1 OR NTRK1-3 Alterations

lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated

chemotherapy regimen
tyrosine
ROS1
lymphoma
solid tumour
  • 0 views
  • 03 Feb, 2021
  • 25 locations
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.

entrectinib
cancer
brain tumor
ROS1
solid tumour
  • 0 views
  • 22 Aug, 2021
  • 5 locations
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3 ROS1 or ALK Gene Fusions.

NTRK1/2/3, ROS1 or ALK gene fusions to direct such patients through an ongoing clinical trial with entrectinib when appropriate. An exploratory translational program is also correlated to this trial in

undifferentiated pleomorphic sarcoma
soft tissue sarcoma
angiosarcoma
x-rays
metastasis
  • 40 views
  • 19 Feb, 2021
  • 15 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

cytokines
alpha-fetoprotein
hematopoietic growth factors
cns tumor
bone marrow infiltration
  • 997 views
  • 12 Sep, 2021
  • 114 locations
Study of Lorlatinib in ROS1 Rearranged NSCLC

This is a phase II, multi-center, single arm study of lorlarinib as a single agent in patients with ROS1-rearranged advanced NSCLC.

platinum doublet
proto-oncogene tyrosine-protein kinase ros
ROS1
cancer chemotherapy
kidney function test
  • 0 views
  • 25 Jan, 2021
  • 1 location
Study of Crizotinib for ROS1 and MET Activated Lung Cancer

called ROS1 or MET. The purpose of this study is to look at how effective crizotinib is at treating ROS1 or MET mutated non-small cell lung cancer. Crizotinib, also called XALKORI, is a

squamous non-small cell lung cancer
crizotinib
ROS1
cancer
measurable disease
  • 0 views
  • 11 Apr, 2021
  • 1 location